Head and Neck Cancer Clinical Trial
— BOOMOfficial title:
Phase IV Study on the Feasibility of a Preventative/Therapeutic Approach With Benzydamine Oromucosal Solution in Radiation-induced Oral Mucositis (OM) in Patients With Head and Neck Cancer (HNC)
Verified date | November 2022 |
Source | Aziende Chimiche Riunite Angelini Francesco S.p.A |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the present study is to collect data on the feasibility of a preventative/therapeutic approach of radiation-induced oral mucositis with benzydamine oromucosal solution (mouthwash) in patients with head and neck cancer.
Status | Completed |
Enrollment | 100 |
Est. completion date | September 5, 2022 |
Est. primary completion date | September 5, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male and female patients of any ethnic origin =18 years of age. - Patients diagnosed with stage III or IV Head and Neck cancer (histologic or cytologic diagnosis), according to VIII AJCC staging system, who are candidate and are about to start RT, with or without concomitant CT, with curative intent, either with exclusive or postoperative intent. - Eastern Cooperative Oncology Group (ECOG) performance status with a score of 0, or 1, or 2. - Patients legally capable of giving their consent to participate in the study and available to sign and date the written informed consent and the Declaration of consent for the processing of personal data. - Women of childbearing potential or with no menses for a period < 12 months must have a negative pregnancy test at Visit 0 and have to agree not to start a pregnancy from the signature of the informed consent up to the end of the study, using an appropriate birth control method, such as combined oestrogen-progestin containing hormonal contraceptives (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g., oral, injectable, implantable), intrauterine device (IUD) or Intrauterine hormone-releasing System (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence. The following definitions will be considered: - Woman of childbearing potential (WOCBP): i.e., fertile, following menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Exclusion Criteria: - Patients with reported allergy to benzydamine or another component of the formulation used. - Any contraindications listed in the local product's Summary of Product Characteristics (SmPCs). - Patients with prior head and neck RT (in the previous 6 months), or patient who received a palliative treatment. - Patients with distant metastatic disease and/or severe cognitive impairment and/or clinically symptomatic brain metastases and/or patients with significant comorbid conditions. - Patients with mucositis due to other medical conditions (e.g., gastro-oesophageal reflux, autoimmune disease, etc.). - Patients who use other oromucosal products (over the counter or prescription) for the same disease. - Prescription of other rinses (anaesthetics like "magic mouthwashes" or others), except from sodium bicarbonate rinses. - Use of chlorhexidine, other anti-inflammatory mouthwashes solutions, misoprostol, granulocyte macrophage colony-stimulating factor (GM-CSF) and sucralfate gel. - Employment of antifungal or antibiotic drugs as prophylaxis for mucositis; any therapeutic use in case of overt clinical infections is allowed. - Patients treated with other therapies that can cause mucositis, except for the therapies for their primary condition. - Patients treated with any topical anti-inflammatory/analgesic products for the mucositis. - Any other product that can interfere with the evaluation of pain or inflammatory state, according to the Investigator's assessment. |
Country | Name | City | State |
---|---|---|---|
Hungary | Orszagos Onkologiai Intezet, Gyogyszertar | Budapest | |
Hungary | Debreceni Egyetem Klinikai Kozpont, Intezeti Gyogyszertar | Debrecen | |
Hungary | Petz Aladar Egyetemi Oktato Korhaz, Intezeti Gyogyszertar, | Gyor | |
Hungary | Somogy Megyei Kaposi Mor Oktato Korhaz - Eszaki Tomb, 1. Emelet, 4. Szarny, Klinikai - Vizsgalati Egyseg. | Kaposvár | |
Hungary | Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz Klinikai Kutatasi Osztaly | Nyíregyháza | |
Hungary | Csolnoky Ferenc Korhaz, Onkologiai Centrum Sugarterapias Osztaly | Veszprém | |
Poland | Centrum Onkologii im. Prof. Franciszka Lukaszczyka Apteka Szpitalna | Bydgoszcz | |
Poland | Szpitale Pomorskie Sp. z o. o., | Gdynia | |
Poland | Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii im. M. Kopernika w Lodzi, - Lódzkie | Lódz | |
Poland | Mazowiecki Szpital Wojewódzki im. sw. Jana Pawla II w Siedlcach - | Siedlce |
Lead Sponsor | Collaborator |
---|---|
Aziende Chimiche Riunite Angelini Francesco S.p.A | PPD |
Hungary, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of responders | The effectiveness of benzydamine oromucosal solution (mouthwash) in the prevention/tratment of radiation-induced oral mucositis in Head and Neck cancer patients is evaluated as the number of responders, expressed in percentage, defined as the number of head and neck cancer patients with oral mucositis pain intensity <5 in the Numeric Rating Scale. | Up to 7 weeks | |
Secondary | Number of compliant patients to Benzydamine treatment. | The compliance to the treatment is calculated at the end of the study. A patient is considered compliant to the benzydamine treatment if he/she takes =80% of the total dose assigned by the Investigator. | Up to 7 weeks | |
Secondary | Change score in the World Health Organization oral mucositis grading scale. | The severity of oral mucositis is evaluated using the World Health Organization (WHO) oral mucositis grading scale.
The Investigator gives a score corresponding to the grade of mucositis of the patient, from "0" = "None" to "4" = "Life-threatening", "Oral alimentation impossible". |
Up to 7 weeks | |
Secondary | Number of days of duration of severe oral mucositis. | The duration of severe oral mucositis (grade 3 or 4 on the World Health Organization oral mucositis grading scale) is assessed. | Up to 7 weeks | |
Secondary | Time of onset of severe oral mucositis. | Time of onset of severe oral mucositis (grade 3 or 4 on the World Health Organization oral mucositis grading scale) is assessed. | Up to 7 weeks | |
Secondary | Percentage change in body weight | The percentage change in body weight from baseline is assessed. | Up to 7 weeks | |
Secondary | Number of days of duration of Radiotherapy/Chemotherapy | Radiotherapy/Chemotherapy is assessed as number of days of duration of therapy. | Up to 7 weeks | |
Secondary | Number of days of discontinuation of Radiotherapy/Chemotherapy | Radiotherapy/Chemotherapy is assessed in terms of days of therapy discontinuation. | Up to 7 weeks | |
Secondary | Dose modifications of Radiotherapy/Chemotherapy | Radiotherapy/Chemotherapy is evaluated as dose modifications of therapy. | Up to 7 weeks | |
Secondary | Delays in Radiotherapy/Chemotherapy | Radiotherapy/Chemotherapy is evaluated as days of delay in therapy. | Up to 7 weeks | |
Secondary | Number of days of hospitalization. | The healthcare resources consumed in terms of number of days of hospitalization due to oral mucositis are evaluated. | Up to 7 weeks | |
Secondary | Change in QoL (EORTC QLQ C-30) from baseline | The health-related quality of life is measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30) | Up to 7 weeks | |
Secondary | Change in QoL (EORTC QLQ-H&N35) from baseline | The health-related quality of life is measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck (EORTC QLQ-H&N35). | Up to 7 weeks | |
Secondary | Number and type of opioid analgesics | The use of opioid analgesics prescribed for oral mucositis pain is assessed. | Up to 7 weeks | |
Secondary | Frequency of adverse events | AEs occurred during a clinical trial are assessed by the Investigator in terms of seriousness and relationship with the investigational product. | Up to 7 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |